The new data comes from the 1,162-subject LUCENT-1 trial – first unveiled last year – which compared induction treatment with the anti-IL-23p19 antibody to placebo in patients with moderately ...

Hepatosplenic T-cell lymphoma. Management. Splenectomy, antibiotic therapy and chemotherapy with cyclophosphamide. A 58-year-old man with a 35-year history of Crohn's disease presented to our IBD ...